Volume | 8,496 |
|
|||||
News | (1) | ||||||
Day High | 0.702 | Low High |
|||||
Day Low | 0.6602 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Virax Biolabs Group Ltd | VRAX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.702 | 0.6602 | 0.702 | 0.70 | 0.6636 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
89 | 8,496 | $ 0.6971444 | $ 5,923 | - | 0.6133 - 5.445 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:20:44 | 8 | $ 0.7172 | USD |
Virax Biolabs Group Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.09M | 1.56M | - | 9k | -5.46M | -3.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Virax Biolabs News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRAX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.6898 | 0.74 | 0.6133 | 0.6667015 | 11,989 | 0.0102 | 1.48% |
1 Month | 0.706 | 0.896855 | 0.6133 | 0.7646847 | 24,181 | -0.006 | -0.85% |
3 Months | 0.81 | 1.09 | 0.6133 | 0.8682982 | 38,152 | -0.11 | -13.58% |
6 Months | 2.82 | 2.82 | 0.6133 | 1.44 | 114,196 | -2.12 | -75.18% |
1 Year | 4.30 | 5.445 | 0.6133 | 3.14 | 169,943 | -3.60 | -83.72% |
3 Years | 200.00 | 290.00 | 0.6133 | 42.06 | 1,005,964 | -199.30 | -99.65% |
5 Years | 200.00 | 290.00 | 0.6133 | 42.06 | 1,005,964 | -199.30 | -99.65% |
Virax Biolabs Description
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. |